Should I buy or sell Revance Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVNC shares. View RVNC analyst ratings or view top-rated stocks .

What is Revance Therapeutics' stock price target for 2024?

8 Wall Street research analysts have issued 1-year price objectives for Revance Therapeutics' shares. Their RVNC share price targets range from $12.00 to $42.00. On average, they anticipate the company's stock price to reach $25.33 in the next year. This suggests a possible upside of 257.3% from the stock's current price. View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts .

How have RVNC shares performed in 2023?

Revance Therapeutics' stock was trading at $18.46 on January 1st, 2023. Since then, RVNC shares have decreased by 61.6% and is now trading at $7.09. View the best growth stocks for 2023 here .

When is Revance Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our RVNC earnings forecast .

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.28. The biopharmaceutical company had revenue of $56.78 million for the quarter, compared to the consensus estimate of $58.49 million. Revance Therapeutics had a negative net margin of 193.42% and a negative trailing twelve-month return on equity of 903.28%.

What ETFs hold Revance Therapeutics' stock?

ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) . iShares U.S. Pharmaceuticals ETF (IHE) .

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com . Mark Foley has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS) , Exelixis (EXEL) , SCYNEXIS (SCYX) , AbbVie (ABBV) , Myovant Sciences (MYOV) , Nektar Therapeutics (NKTR) , Sorrento Therapeutics (SRNE) , Bausch Health Companies (BHC) , Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO) .

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Polar Capital Holdings Plc (4.74%), Invesco Ltd. (3.31%), FMR LLC (2.16%), Rubric Capital Management LP (1.82%), Rubric Capital Management LP (1.82%) and Wellington Management Group LLP (1.23%). Insiders that own company stock include Angus C Russell , Aubrey Rankin , Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie , Mark J Foley and Tobin Schilke. View institutional ownership trends .

How do I buy shares of Revance Therapeutics?

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Revance Therapeutics Stock Price, News & Analysis (NASDAQ:RVNC)

$7.09

+0.04 (+0.57%)

(As of 12/7/2023 ET)

Compare

Today's Range: $6.93
▼
$7.20
50-Day Range: $5.81
▼
$11.47
52-Week Range: $5.72
▼
$37.98

Volume: 1.16 million shs
Average Volume: 1.62 million shs
Market Capitalization: $622.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.33

Revance Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 257.3% Upside
$25.33 Price Target
Short Interest: Bearish
16.66% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.88
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.05) to ($2.09) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

205th out of 960 stocks

Pharmaceutical Preparations Industry

53rd out of 381 stocks

4.4

Analyst's Opinion

Consensus Rating
Revance Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.33, Revance Therapeutics has a forecasted upside of 257.3% from its current price of $7.09.
Amount of Analyst Coverage
Revance Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
16.66% of the outstanding shares of Revance Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Revance Therapeutics has a short interest ratio ("days to cover") of 7.1.
Change versus previous month
Short interest in Revance Therapeutics has recently increased by 13.15%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Revance Therapeutics does not currently pay a dividend.
Dividend Growth
Revance Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Revance Therapeutics has received a 74.80% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Revance Therapeutics is -0.88.

0.0

News and Social Media Coverage

Search Interest
Only 3 people have searched for RVNC on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Revance Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Revance Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.10% of the stock of Revance Therapeutics is held by insiders.
Percentage Held by Institutions
93.28% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Revance Therapeutics are expected to grow in the coming year, from ($3.05) to ($2.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Revance Therapeutics is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Revance Therapeutics is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Revance Therapeutics has a P/B Ratio of 47.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Revance Therapeutics Stock (NASDAQ:RVNC)

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

RVNC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RVNC Stock News Headlines

November 29, 2023 | seekingalpha.com

Revance Therapeutics: Not Even Daxxify Can Treat Investor Frown Lines

November 28, 2023 | americanbankingnews.com

Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Rating of "Moderate Buy" by Analysts

December 8, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.

November 22, 2023 | markets.businessinsider.com

What 10 Analyst Ratings Have To Say About Revance Therapeutics

November 10, 2023 | markets.businessinsider.com

Revance Therapeutics Maintains Buy Rating Despite Decreased Share Value: New Pricing Strategy Shows Promising Results

November 10, 2023 | markets.businessinsider.com

Revance Therapeutics: Adapting Strategy and Promising Outlook Justify Buy Rating

November 10, 2023 | finance.yahoo.com

Analysts Just Slashed Their Revance Therapeutics, Inc. (NASDAQ:RVNC) EPS Numbers

November 9, 2023 | finance.yahoo.com

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Call Transcript

December 8, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

November 9, 2023 | finance.yahoo.com

Q3 2023 Revance Therapeutics Inc Earnings Call

November 8, 2023 | finance.yahoo.com

Revance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to Say

November 8, 2023 | finance.yahoo.com

Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics

November 8, 2023 | finance.yahoo.com

Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update

November 1, 2023 | finance.yahoo.com

Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

October 26, 2023 | finance.yahoo.com

DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions

October 24, 2023 | msn.com

Barclays Maintains Revance Therapeutics (RVNC) Overweight Recommendation

September 22, 2023 | 247wallst.com

Goldman Sachs Maintains Revance Therapeutics Buy Recommendation

September 20, 2023 | benzinga.com

Discontinuation Of Opul Business Weighs On Botox Rival Revance Therapeutics: Analyst Sees Non-Cash Impairment Charge In Millions

September 19, 2023 | seekingalpha.com

Revance down 16% as investor day update fails to impress

September 19, 2023 | markets.businessinsider.com

What's Going On With Botox Rival Revance Therapeutics' Stock Today?

September 19, 2023 | finance.yahoo.com

Revance Provides Corporate Update at Investor Day

September 18, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revance Therapeutics (RVNC) and PTC Therapeutics (PTCT)

September 15, 2023 | msn.com

Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn

September 15, 2023 | seekingalpha.com

Revance's FDA Nod: Beauty, Brains, And Balance Sheets

September 6, 2023 | finance.yahoo.com

Revance Therapeutics (RVNC): A Smart Investment or a Value Trap? An In-Depth Exploration

August 22, 2023 | finance.yahoo.com

Revance to Host Investor Day on September 19, 2023

August 22, 2023 | finance.yahoo.com

‘Load Up,’ Says Goldman Sachs About These 2 ‘Strong Buy’ Stocks

See More Headlines

Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RVNC
CUSIP: N/A
CIK: 1479290
Web: www.revance.com
Phone: (615) 724-7755
Fax: 510-742-3401
Employees: 534
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $25.33
High Stock Price Target: $42.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +257.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.99)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-356,420,000.00
Net Margins: -193.42%
Pretax Margin: -193.28%
Return on Equity: -903.28%
Return on Assets: -59.67%

Debt

Debt-to-Equity Ratio: 14.20
Current Ratio: 4.73
Quick Ratio: 4.17

Sales & Book Value

Annual Sales: $214.16 million
Price / Sales: 2.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.15 per share
Price / Book: 47.27

Miscellaneous

Outstanding Shares: 87,813,000
Free Float: 84,652,000
Market Cap: $622.59 million
Optionable: Optionable
Beta: 0.83

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Mark J. Foley (Age 58)
CEO & Director
Comp: $1.33M
Mr. Dustin S. Sjuts (Age 43)
President
Comp: $911.67k
Mr. Tobin C. Schilke (Age 48)
CFO & Principal Accounting Officer
Comp: $753.68k
Mr. Dwight Moxie (Age 47)
Senior VP, General Counsel & Corporate Secretary
Comp: $743.77k
Jessica Serra
Head of Investor Relations & ESG
Ms. Jeanie D. Herbert
Senior Director of Investor Relations & Corporate Communications
Ms. Taryn Conway
Vice President of Marketing
Ms. Amie Krause
Chief People Officer
Dr. Conor Gallagher
Head of Medical Affairs & Aesthetics
Dr. David A. Hollander M.B.A. (Age 49)
M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RVNC Stock Analysis - Frequently Asked Questions

Should I buy or sell Revance Therapeutics stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVNC shares.
View RVNC analyst ratings or view top-rated stocks.
What is Revance Therapeutics' stock price target for 2024?: 8 Wall Street research analysts have issued 1-year price objectives for Revance Therapeutics' shares. Their RVNC share price targets range from $12.00 to $42.00. On average, they anticipate the company's stock price to reach $25.33 in the next year. This suggests a possible upside of 257.3% from the stock's current price.
View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts.
How have RVNC shares performed in 2023?: Revance Therapeutics' stock was trading at $18.46 on January 1st, 2023. Since then, RVNC shares have decreased by 61.6% and is now trading at $7.09.
View the best growth stocks for 2023 here.
When is Revance Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our RVNC earnings forecast.
How were Revance Therapeutics' earnings last quarter?: Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.28. The biopharmaceutical company had revenue of $56.78 million for the quarter, compared to the consensus estimate of $58.49 million. Revance Therapeutics had a negative net margin of 193.42% and a negative trailing twelve-month return on equity of 903.28%.
What ETFs hold Revance Therapeutics' stock?: ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What is Mark Foley's approval rating as Revance Therapeutics' CEO?: 7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.
What other stocks do shareholders of Revance Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).
Who are Revance Therapeutics' major shareholders?: Revance Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Polar Capital Holdings Plc (4.74%), Invesco Ltd. (3.31%), FMR LLC (2.16%), Rubric Capital Management LP (1.82%), Rubric Capital Management LP (1.82%) and Wellington Management Group LLP (1.23%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie, Mark J Foley and Tobin Schilke.
View institutional ownership trends.
How do I buy shares of Revance Therapeutics?: Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RVNC) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Revance Therapeutics Stock Price, News & Analysis (NASDAQ:RVNC)

Revance Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Revance Therapeutics Stock (NASDAQ:RVNC)

RVNC Stock Price History

RVNC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RVNC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™